Formulary guidance and transparency from P&T to point of care


Reality Check on Diabetes

Market access for type 2 diabetes treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Increasing percentage of restricted lives across commercial and health exchange formularies
  • Class Trends: How manufacturers are staying ahead with a focus on predictive market access coverage rather than the lagging indicator of script data
  • Key Findings: The heavyweight fight for lowest copay tiers via payer contracting continues on

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team.  Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.